NIH R01 · 2024
Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL
Abstract: Philadelphia chromosome-positive (Ph+) leukemia is caused by BCR-ABL1, a constitutively active fusion kinase. Tyrosine kinase inhibitors (TKIs) targeting the ATP site of BCR-ABL1 are effective in treating chronic-phase chronic myeloid leukemia (CP-CML) yet minimally effective at treating blast-phase CML and Ph+ acute lymphoblastic leukemia. In the 20 years since the approval of the first TKI in all of medicine, imatinib, TKIs have dramatically improved survival of patients with CP-CML, resulting in a projected increase of CML prevalence from 70,000 Americans in 2010 to 180,000 in 2050. Despite this progress, TKI-resistant CML remains a challenge, with >1,000 deaths annually in the…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.